Herald Writer
BOTHELL — Nastech Pharmaceutical Co. said this week that the U.S. Food and Drug Administration has accepted its new drug application for a nasal spray to treat osteoporosis.
While the FDA reviews the application, the Bothell company said it is working on marketing and distribution agreements for the drug.
Nastech's new spray would be a generic drug similar to Miacalcin nasal spray, which is made by Swiss-based Novartis AG. Last year, Miacalcin sales reached $239 million in the United States and $389 million worldwide.
“It's a growing market,” said Matthew Haines, spokesman for Nastech.
Source: http://www.heraldnet.com/Stories/04/2/19/18205403.cfm
[Editor: The preceding article was not written by A4M/WHN]
